Skip to main content
Erschienen in: Indian Journal of Pediatrics 3/2012

01.03.2012 | Original Article

Intravenous Diazepam, Midazolam and Lorazepam in Acute Seizure Control

verfasst von: Geeta Gathwala, Mayank Goel, Jagjit Singh, Kundan Mittal

Erschienen in: Indian Journal of Pediatrics | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the safety and efficacy of three benzodiazepine drugs: Lorazepam, Midazolam and Diazepam, when given parenterally in the control of acute seizure.

Methods

One hundred and twenty children of either sex in the age group 6 month to 14 years brought convulsing to the pediatric emergency services, were enrolled in the study. These were randomised to three equal groups of 40 patients each; Group A—received diazepam, Group B—received midazolam, Group C—received lorazepam. End of seizure episode (clinically) was defined as cessation of visible epileptic phenomenon or return of purposeful response to external stimuli within 15 min of drug administration. A stopwatch was used to measure various time intervals accurately. The patient’s vitals were monitored and recorded in a predesigned performa. The primary outcome was the time to seizure cessation and secondary outcome was the side effects of the drugs. Data obtained was analysed statistically using student’s t-test and chi-square test.

Results

Mean duration to clinical seizure cessation was comparable among the three groups. For diazepam group it was 84.94 ± 38.56 s, for midazolam group it was 92.69 ± 25.97 s, for lorazepam group it was 91.12 ± 23.58 s. Number of patients with any abnormality in seizure cessation were significantly higher in diazepam group [11/40 (27.5%)] when compared to the midazolam [4/40 (10%)] and lorazepam group [2/40 (5%)]. Number of patients requiring 2nd dose to control seizures was significantly higher [4/40 (10%)] in diazepam group when compared to lorazepam group [0/40 (0%)] but diazepam and midazolam and midazolam and lorazepam were comparable in this aspect.All the three drugs were comparable in terms of side effects except excessive somnolence which was significantly higher in diazepam group.

Conclusions

All the three groups were comparable in terms of time to clinical seizure cessation, seizure recurrence and uncontrolled seizures after drug administration. However, number of patients requiring second dose to control seizures were significantly higher in diazepam group when compared to lorazepam group. Excessive somnolence and sedation occurred more frequently with diazepam.
Literatur
1.
Zurück zum Zitat Working group on status epilepticus. Treatment of Convulsive Status Epilepticus: Recommendation of the epilepsy foundation of America’s working group on status epilepticus. JAMA. 1993;270:854–9.CrossRef Working group on status epilepticus. Treatment of Convulsive Status Epilepticus: Recommendation of the epilepsy foundation of America’s working group on status epilepticus. JAMA. 1993;270:854–9.CrossRef
2.
Zurück zum Zitat Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989;83:323–31.PubMed Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989;83:323–31.PubMed
3.
Zurück zum Zitat Celesia GG. Prognosis in convulsive status epilepticus. Adv Neurol. 1983;34:55–8.PubMed Celesia GG. Prognosis in convulsive status epilepticus. Adv Neurol. 1983;34:55–8.PubMed
4.
Zurück zum Zitat Haafiz A, Kissoon N. Status epilepticus: current concepts. Pediatr Emerg Care. 1999;15:119–29.PubMedCrossRef Haafiz A, Kissoon N. Status epilepticus: current concepts. Pediatr Emerg Care. 1999;15:119–29.PubMedCrossRef
5.
Zurück zum Zitat Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin N Am. 2001;48:683–94.CrossRef Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin N Am. 2001;48:683–94.CrossRef
6.
Zurück zum Zitat Wolf SM, Ochoa JG, Conway Jr EE. Seizure management in pediatric patients for the nineties. Pediatr Ann. 1998;27:653–64.PubMed Wolf SM, Ochoa JG, Conway Jr EE. Seizure management in pediatric patients for the nineties. Pediatr Ann. 1998;27:653–64.PubMed
7.
Zurück zum Zitat Friedman MJ, Sharieff GQ. Seizures in children. Pediatr Clin N Am. 2006;53:257–77.CrossRef Friedman MJ, Sharieff GQ. Seizures in children. Pediatr Clin N Am. 2006;53:257–77.CrossRef
8.
Zurück zum Zitat Qureshi A, Wassmer E, Davies P, Berry K, Whitehouse WP. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure. 2002;11:141–4.PubMedCrossRef Qureshi A, Wassmer E, Davies P, Berry K, Whitehouse WP. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure. 2002;11:141–4.PubMedCrossRef
9.
Zurück zum Zitat Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out of hospital status epilepticus. N Engl J Med. 2001;345:631–7.PubMedCrossRef Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out of hospital status epilepticus. N Engl J Med. 2001;345:631–7.PubMedCrossRef
10.
Zurück zum Zitat Aicardi J, Chevrie JJ. Convulsive status epilepticus in infants and children. A study of 239 cases. Epilepsia. 1970;11:187–97.PubMedCrossRef Aicardi J, Chevrie JJ. Convulsive status epilepticus in infants and children. A study of 239 cases. Epilepsia. 1970;11:187–97.PubMedCrossRef
12.
Zurück zum Zitat Riss J, Cloyd J, Gates J, Collin S. Benzodiazepines in epilepsy: Pharmacology and pharmokinetics. Acta Neurol Scand. 2008;118:69–86.PubMedCrossRef Riss J, Cloyd J, Gates J, Collin S. Benzodiazepines in epilepsy: Pharmacology and pharmokinetics. Acta Neurol Scand. 2008;118:69–86.PubMedCrossRef
13.
Zurück zum Zitat Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev. 2000;22:239–42.PubMedCrossRef Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev. 2000;22:239–42.PubMedCrossRef
14.
Zurück zum Zitat Shah I, Deshmukh CT. Intramuscular midazolam vs. intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72:667–70.PubMedCrossRef Shah I, Deshmukh CT. Intramuscular midazolam vs. intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72:667–70.PubMedCrossRef
15.
Zurück zum Zitat Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37:682–8.PubMedCrossRef Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37:682–8.PubMedCrossRef
16.
Zurück zum Zitat Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM. 2002;95:225–31.PubMedCrossRef Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM. 2002;95:225–31.PubMedCrossRef
17.
Zurück zum Zitat Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249:1452–4.PubMedCrossRef Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249:1452–4.PubMedCrossRef
18.
Zurück zum Zitat Mitchell WG, Crawford TO. Lorazepam is the treatment of choice for status epilepticus. J Epilepsy. 1990;3:7–10.CrossRef Mitchell WG, Crawford TO. Lorazepam is the treatment of choice for status epilepticus. J Epilepsy. 1990;3:7–10.CrossRef
19.
Zurück zum Zitat Rivera R, Segnini M, Baltodano A, Perez V. Midazolam in the treatment of status epilepticus in children. Critical Care Med. 1993;21:991–4.CrossRef Rivera R, Segnini M, Baltodano A, Perez V. Midazolam in the treatment of status epilepticus in children. Critical Care Med. 1993;21:991–4.CrossRef
Metadaten
Titel
Intravenous Diazepam, Midazolam and Lorazepam in Acute Seizure Control
verfasst von
Geeta Gathwala
Mayank Goel
Jagjit Singh
Kundan Mittal
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Indian Journal of Pediatrics / Ausgabe 3/2012
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-011-0505-y

Weitere Artikel der Ausgabe 3/2012

Indian Journal of Pediatrics 3/2012 Zur Ausgabe

Symposium on PGIMER Protocols in Neurological Emergencies

Approach to Headache in Emergency Department

Symposium on PGIMER Protocols on Neurological Emergencies

Fainting Attacks in Children

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.